Structure-activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif
Overview
Authors
Affiliations
Cyclic and linear peptides containing the Asn-Gly-Arg (NGR) motif have proven useful for delivering various anti-tumor compounds and viral particles to tumor vessels. We have investigated the role of cyclic constraints on the structure and tumor-homing properties of NGR peptides using tumor necrosis factor-alpha (TNF) derivatives containing disulfide-bridged (CNGRC-TNF) and linear (GNGRG-TNF) NGR domains. Experiments carried out in animal models showed that both GNGRG and CNGRC can target TNF to tumors. However, the anti-tumor activity of CNGRC-TNF was >10-fold higher than that of GNGRG-TNF. Molecular dynamic simulation of cyclic CNGRC showed the presence of a bend geometry involving residues Gly(3)-Arg(4). Molecular dynamic simulation of the same peptide without disulfide constraints showed that the most populated and thermodynamically favored configuration is characterized by the presence of a beta-turn involving residues Gly(3)-Arg(4) and hydrogen bonding interactions between the backbone atoms of Asn(2) and Cys(5). These results suggest that the NGR motif has a strong propensity to form beta-turn in linear peptides and may explain the finding that GNGRG peptide can target TNF to tumors, albeit to a lower extent than CNGRC. The disulfide bridge constraint is critical for stabilizing the bent conformation and for increasing the tumor targeting efficiency.
Research Progress on Cyclic-Peptide Functionalized Nanoparticles for Tumor-Penetrating Delivery.
Wang C, Shen Z, Chen Y, Wang Y, Zhou X, Chen X Int J Nanomedicine. 2024; 19:12633-12652.
PMID: 39624118 PMC: 11609414. DOI: 10.2147/IJN.S487303.
Radiolabeled NGR-Based Heterodimers for Angiogenesis Imaging: A Review of Preclinical Studies.
Trencsenyi G, Halmos G, Kepes Z Cancers (Basel). 2023; 15(18).
PMID: 37760428 PMC: 10526435. DOI: 10.3390/cancers15184459.
Charoenkwan P, Chiangjong W, Nantasenamat C, Moni M, Lio P, Manavalan B Pharmaceutics. 2022; 14(1).
PMID: 35057016 PMC: 8779003. DOI: 10.3390/pharmaceutics14010122.
Lee S, Moody I, Zeng Z, Fleischer E, Weiss G, Shea K ACS Appl Bio Mater. 2022; 4(3):2704-2712.
PMID: 35014309 PMC: 9109703. DOI: 10.1021/acsabm.0c01631.
Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics.
Lucana M, Arruga Y, Petrachi E, Roig A, Lucchi R, Oller-Salvia B Pharmaceutics. 2021; 13(12).
PMID: 34959346 PMC: 8708026. DOI: 10.3390/pharmaceutics13122065.